HLN250516P12500
- 0.00
- 0.000.00%
Haleon Newsroom
Haleon's Results Didn't Surprise -- Market Talk
Haleon's Vitamins & Supplements Business Weakness in Focus Among Results -- Market Talk
Haleon Q1 Revenues Down, Organic Revenues Rise; Backs FY25 Outlook
Haleon Organic Revenue Rose With Increases in All Regions, Categories
Haleon Expects Macroeconomic Environment to Remain Challenging, Uncertain
Haleon Continues to Deliver Against Capital Allocation Priorities
Haleon Sees 2025 Adjusted Operating Profit Growth Ahead of Revenue Growth
Haleon Backs 2025 View
Haleon 1Q Rev GBP2.85B
Haleon 1Q Organic Revenue Growth up 3.5%
Haleon To Go Ex-Dividend On April 25th, 2025 With 0.11661 USD Dividend Per Share
Haleon PLC Executes Share Buyback to Optimize Capital Structure
Haleon Acquires Chinese JV
Haleon: Deal Expected to Close Within Next Three Mos
Haleon Bought 33% Interest in December 2024
Haleon Buys 33% Interest in Tianjin TSKF Pharmaceutical
AI replacing animal experiments? A message from the FDA has left "monkey breeders" feeling devastated, and experts state that "we are still far from the stage of implementation."
① The news that the USA FDA has publicly stated it will gradually replace animal testing requirements has led to an increase in the stock prices of AI pharmaceutical companies, impacting traditional drug evaluation CRO companies; ② Some believe this action represents a trend in Industry development. However, others believe that it is far from being implementable.
Moody's Upgrades Haleon on Strong Business Profile
KKR Outbids Competitors To Secure $2.9 Billion Karo Healthcare Takeover
Haleon Price Target Raised to 460 GBp From 457 GBp at Berenberg